上海毕得医药科技股份有限公司 董事、高级管理人员离职管理制度 第二章 离职情形与生效条件 第三条 董事可以在任期届满以前辞任。董事辞任应向公司提交书面辞任报 告。董事辞任的，自公司收到辞任报告之日辞任生效，公司将在两个交易日内 披露有关情况。出现下列规定情形的，在改选出的董事就任前，原董事仍应当 依照法律、行政法规和公司章程规定，履行董事职务： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员 低于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员低于法定最低人数，或者 欠缺担任召集人的会计专业人士； （三）独立董事辞任导致公司董事会或者专门委员会中独立董事所占比例 不符合法律法规或者公司章程规定，或者独立董事中欠缺会计专业人士。 第一章 总则 第一条 为规范上海毕得医药科技股份有限公司（以下简称"公司"）董事、 高级管理人员离职管理，保障公司治理稳定性及股东合法权益，根据《中华人 民共和国公司法》（以下简称《公司法》）《上市公司章程指引》《上海证券交易 所科创板股票上市规则》等法律法规、规范性文件及《上海毕得医药科技股份 有限公司章程》（以下简称"公司章程"）的有关规定，结合公司实际 ...

证券代码：688073 证券简称：毕得医药 公告编号：2026-005 上海毕得医药科技股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2026 年 2 月 9 日 9 点 30 分 召开地点：上海市杨浦区翔殷路 999 号 3 幢 6 层会议室 （五） 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 9 日 至2026 年 2 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 股东会召开日期：2026年2月9日 本次股东会采用的网络投票系统：上海证 ...

南财智讯1月23日电，毕得医药公告，公司控股股东、实际控制人兼董事长、总经理戴岚女士通过集中 竞价交易方式累计减持公司股份148,835股，占公司总股本的0.16%，本次减持计划已实施完毕。 ...

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

Group 1 - Bid Medicine's stock price fell by 5.04% on January 20, closing at 66.00 yuan per share, with a trading volume of 52.74 million yuan and a turnover rate of 1.81%, resulting in a total market capitalization of 5.998 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.12% during this period [1] - Bid Medicine focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] Group 2 - Among the top ten circulating shareholders of Bid Medicine, a fund under E Fund, specifically E Fund Value Growth Mixed Fund (110010), entered the top ten with 900,000 shares, accounting for 2.08% of circulating shares [2] - The estimated floating loss for E Fund Value Growth Mixed Fund today is approximately 3.15 million yuan, with a total floating loss of 4.077 million yuan during the three-day decline [2] - E Fund Value Growth Mixed Fund has a total asset size of 3.288 billion yuan, with a year-to-date return of 3.74% and a one-year return of 38.06% [2]

Group 1 - The core viewpoint of the news highlights the performance of the TaiKang Medical Health Fund, which saw declines in its two share classes, with Class C down by 13.45% and Class A down by 13.02% in 2025 [2][3] - The top ten holdings of the TaiKang Medical Health Fund in the third quarter of 2025 included companies such as JingTai Holdings, Kanglong Chemical, Fangzhou Jianke, SanSheng Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [2] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., and has been with TaiKang since July 2019, becoming the fund manager on March 8, 2022 [2]

Group 1 - The core viewpoint of the news is that the Taikang Medical Health Fund has experienced significant declines in its stock performance for both Class C and Class A shares, with decreases of 13.45% and 13.02% respectively in 2025 [1][2] - The top ten holdings of the fund as of the third quarter of 2025 include companies such as Jingtai Holdings, Kanglong Chemical, Fangzhou Jianke, Sanofi Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [1] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., Ltd. and has been with Taikang since July 2019, becoming the fund manager on March 8, 2022 [1]

Market Overview - The A-share market experienced a collective decline on January 13, with the Shanghai Composite Index closing at 4163.84 points, down 0.03%, the Shenzhen Component Index down 0.31%, and the ChiNext Index down 0.83% [2] - A total of 2427 stocks rose while 2862 stocks fell, indicating a mixed market sentiment [4] Sector Performance - The healthcare services, lithium mining, precious metals, and insurance sectors showed notable gains, while sectors such as commercial aerospace, communication equipment, and shipbuilding faced declines [4] - The healthcare services sector rose by 6.61%, lithium mining by 4.86%, and precious metals by 3.91% [5] Lithium Mining Sector - Lithium mining stocks surged, with major players like Tibet Summit hitting the daily limit, and companies such as Salt Lake Industry and Ganfeng Lithium rising over 7% [13] - The price of lithium carbonate futures on the Shanghai Futures Exchange surpassed 170,000 yuan per ton, marking a rise of over 9% and reaching a new high since October 2023 [7] Insurance Sector - The insurance sector showed resilience, with China Life Insurance rising over 3% to a market value of 1,279.4 billion yuan, and Ping An Insurance increasing over 2% to a market value of 1,203.4 billion yuan [10][12] - A report from Guojin Securities predicts that new insurance premiums for listed companies will achieve double-digit growth by 2026, driven by the bancassurance channel and increased market share of large insurers [15] AI Healthcare Sector - AI healthcare stocks experienced significant activity, with companies like Di'an Diagnostics and Nossger hitting the daily limit, and others like Meien Health and International Medicine also seeing substantial gains [16] - Nvidia announced a joint investment of $1 billion with Eli Lilly to establish an AI drug laboratory, aiming to accelerate medical discoveries [18] Precious Metals Sector - The precious metals sector saw a rise, with spot gold prices reaching a record high of $4630.28 per ounce [20] - Stocks such as Hunan Silver and Xiaocheng Technology rose over 8%, while other companies like Shandong Gold and Zhongjin Gold also experienced gains [21]

Market Overview - On January 13, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index closing at 4163.84 points, down 0.03% [2] - The Shenzhen Component Index fell by 0.31%, and the ChiNext Index decreased by 0.83% [2][3] - A total of 2427 stocks rose while 2862 stocks fell, indicating a mixed market sentiment [3] Sector Performance - The healthcare services, lithium mining, precious metals, and insurance sectors showed strong performance, while sectors such as commercial aerospace, communication equipment, and shipbuilding faced declines [3][4] - Lithium mining stocks experienced a significant surge, with companies like Tibet Summit reaching a 10% limit up, and others like Salt Lake Co. and Ganfeng Lithium rising over 7% [6][7] Lithium Mining Sector - The lithium mining sector saw a notable rally, with the main contract for lithium carbonate futures on the Shanghai Futures Exchange surpassing 170,000 yuan per ton, marking a rise of over 9% [6] - Key stocks in this sector include: - Tibet Summit: 19.49 yuan, up 9.99%, market cap of 17.8 billion yuan - Ganfeng Lithium: 72.83 yuan, up 7.15%, market cap of 144.5 billion yuan - Salt Lake Co.: 34.24 yuan, up 7.13%, market cap of 181.2 billion yuan [7] Insurance Sector - The financial sector was active, with the insurance sector showing strength. China Life Insurance rose over 3%, reaching 50.94 yuan per share, with a market cap of 1.2794 trillion yuan [10] - China Ping An increased by over 2%, priced at 68.92 yuan per share, with a market cap of 1.2034 trillion yuan [12] - Analysts predict that by 2026, new premium income for listed insurance companies will achieve double-digit growth, driven primarily by the bancassurance channel [15] AI Healthcare Sector - AI healthcare stocks were notably active, with several companies hitting the daily limit up. Notable performers included: - Nossg: 76.48 yuan, up 20.01%, market cap of 7.4 billion yuan - Pruis: 72.24 yuan, up 20.00%, market cap of 5.7 billion yuan - Hongbo Medicine: 56.64 yuan, up 20.00%, market cap of 7.9 billion yuan [18] - Nvidia announced a joint investment of $1 billion with Eli Lilly to establish an AI drug laboratory, which is expected to accelerate medical discoveries [17] Precious Metals Sector - The precious metals sector saw a significant rise, with spot gold prices reaching a record high of $4630.28 per ounce [20] - Key stocks in this sector include: - Hunan Silver: 9.21 yuan, up 9.90%, market cap of 26 billion yuan - Xiaocheng Technology: 38.54 yuan, up 8.72%, market cap of 10.6 billion yuan [21]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Insights - The pharmaceutical sector experienced a weekly return of 7.81%, outperforming the CSI 300 index by 5.03%, ranking 6th among 31 primary sub-industry indices. The medical services sub-sector had the highest weekly increase of 12.34% [3][15] - The report highlights the impact of recent events such as Elon Musk's announcement regarding Neuralink's product mass production in 2026, Arrowhead Pharmaceuticals' promising clinical data for its siRNA therapy ARO-INHBE, and OpenAI's launch of "ChatGPT health," which have driven the sector's performance. The report suggests that while the brain-computer interface theme may be at a short-term emotional peak, AI medical applications still have room for growth [3][14] - Continuous investment in innovative drugs and related assets in the CXO and upstream life sciences sectors is recommended [3][14] Summary by Sections 1. Market Performance - The pharmaceutical sector's monthly return was 4.87%, outperforming the CSI 300 index by 1.37%, ranking 18th among 31 primary sub-industry indices. The medical services sub-sector had the highest monthly increase of 12.19% [15][20] 2. AI Medical Applications - AI applications in healthcare include AI+medical testing, AI+medical large models, AI+imaging, AI+e-commerce/precision marketing, and AI+gene sequencing, with notable companies such as KingMed Diagnostics, Dian Diagnostics, and BGI Genomics leading in these areas [4][16] 3. CXO and Upstream Life Sciences - Key global CXO leaders to watch include WuXi AppTec, WuXi Biologics, and Kelun Pharmaceutical. Domestic clinical CRO leaders include Tigermed and PPD. The report also highlights resource-based CXOs and upstream life sciences companies [5][16] 4. High-end Medical Devices - The report suggests focusing on companies involved in robotic applications, pharmaceutical equipment, and consumer medical devices, as demand is gradually recovering [5][16] 5. Innovative Drugs - Investment opportunities are identified in small nucleic acids, ADCs, and IO dual/multi-antibodies, with specific companies recommended for each category [6][16]